FlynancialAnalyst Posted - 13 hours ago

$MDGL monthly looks even better than weekly... all the chips against that $200 volume support $XBI

FlynancialAnalyst Posted - 13 hours ago

$MDGL Keep a close eye on this $4.58B mc $XBI leader; seeing accumulation against this key $200 level and rising 40/80 wk SMA confluence 94.7% institutionally owned, UP from 79.76% 2yrs ago. 26.32% short float ... #SqueezeIt #BTFD TrendEdge.app/asset/MDGL

vu_jade Posted - 21 hours ago

$MDGL great spot to add if you’ve been on the fence.

Diefreeandsell Posted - 21 hours ago

@homar1 been telling them that, In $iova and other approved names like $tgtx $mdgl $CRSP … Only believe in aporoved names now

ClarityOfPurpose Posted - 21 hours ago

$MDGL BofA and friends covering short positions? :)

NumberWang Posted - 22 hours ago

$MDGL drop last two weeks has been nasty.

ClarityOfPurpose Posted - 22 hours ago

$MDGL Just two weeks away from receiving the Q1 ER and 2024 forecast. I am buying just ahead of that date if there happens to be further price weakness. I think the May 7 ER and webcast will be very positive.

Diefreeandsell Posted - 23 hours ago

$CADL another drop after pop to lower high. Means lower lows coming. Randomized trials are just too damn expensive and time consuming. Fda’s Pazdur made sure struggling biotech’s only hope is for BO with that guantlet to approval. Most will never make but a few did Recently! So why aren’t you buying shares in $IBRX $TGTX $MDGL and $CRSP. Do some real dd on teal co’s with fda

Stock_Titan Posted - 23 hours ago

$MDGL Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 https://www.stocktitan.net/news/MDGL/madrigal-pharmaceuticals-to-release-first-quarter-2024-financial-ssxcx66jxd06.html

Diefreeandsell Posted - 1 day ago

$LABU Sorry friends but IBRX got some exciting news this evening with FDA mktg approval. $ARKK $ALT $MDGL $CRSP https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-immunitybios-bladder-cancer-therapy-2024-04-22/ Some more info if you want to swing in. Good luck to all !

All_just_a_game Posted - 1 day ago

$MDGL Q1 earnings in next few weeks. We will hear from the horses mouth the early launch commentary.

Quantumup Posted - 1 day ago

BofA #MASH Primer~Sees attractive investment opportunity Says Multifactorial nature of #MASH supports multiple MoAs $MDGL $IVA $VKTX $ETNB AKRO $ALGS IONS SGMT LLY NVO PFE NGM REGN ALNY ARWR GILD ALT 📝's space has heated up, w/ >30 players Ests #MASH mkt = $23B by '35:

misterbig Posted - 1 day ago

$MDGL So BofA starts coverage with a $150 target while $VKTX has a valuation of over $7B. Someone at BofA please explain that to me…

All_just_a_game Posted - 1 day ago

$MDGL What a bounce.

NumberWang Posted - 1 day ago

If/when Bios run again, $MDGL and $VKTX are my picks. Kind of hard to get excited with a hawkish $FED though.

Whiskeyunderthebed Posted - 1 day ago

$MDGL this stock should be up today not down, heavily manipulation

BrenFal0919 Posted - 1 day ago

$MDGL $UNH big news here what a discount

DonCorleone77 Posted - 1 day ago

$MDGL $UNH United not requiring prior authorization for Madrigal drug, says JMP JMP Securities says United Healthcare (UNH) is not requiring step therapy or prior authorization for Madrigal Pharmaceuticals' (MDGL) Rezdiffra. Rezdiffra became available on April 9 and United has updated its Pharmacy Benefit Programs Drug List to cover Rezdiffra effective May 1 without requiring step therapy or prior authorization which should ease access to the drug from one of the largest insurers, the analyst tells investors in a research note. The firm models 2024 revenue of $97M versus the consensus of $89M, as it expects demand will be high based on a recent physician survey. Some coverage determinations may not be as favorable as United's, says JMP, which reiterates an Outperform rating on Madrigal with a $397 price target.

UVXYtrading Posted - 1 day ago

$MDGL fuck BoFA and all the other false prophets stealing our $

Tbonesteak1234 Posted - 1 day ago

$MDGL wtf is happening here?

precise Posted - 1 day ago

$MDGL I have to agree with BOFA, too many questions here. Analysts have no idea either:

whateverhappens Posted - 1 day ago

$MDGL will add then…

BrenFal0919 Posted - 1 day ago

$MDGL picked up more , holding , accumulating

Idvst8 Posted - 1 day ago

$MDGL - Kind of amazing they have taken it down to these levels, but the MM's always prey on Launch Revenue. Typically they (all mostly) under-perform out of the sales gate. This should do great in the long run. Too Cheap

DonCorleone77 Posted - 1 day ago

$MDGL BofA starts Madrigal at Underperform amid Rezdiffra launch questions BofA analyst Alexandria Hammond initiated coverage of Madrigal Pharmaceuticals with an Underperform rating and $150 price target. The commercial stage company has received the first FDA approval for fatty liver disease, also known as MASH, though investors have "largely moved past Rezdiffra's best-case scenario FDA approval" and payer pushback given Rezdiffra's $47,000 annual price tag could prompt a slow launch, perpetuating a "short the launch thesis" and providing further downside potential for shares, the analyst argues.

StockMeister2 Posted - 1 day ago

$MDGL Won't you cool me down wash over me https://www.youtube.com/watch?v=WDVifDI1je0

erevnon Posted - 2 days ago

B of A Securities initiates coverage on Madrigal Pharmaceuticals $MDGL at Underperform rating and a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

ClarityOfPurpose Posted - 2 days ago

$MDGL My understanding is that they will get a minimum of a 5-year period of marketing exclusivity for resmetirom, just based on the fact that it is a New Chemical Entity (NCE). Anyone interpret the situation differently?

precise Posted - 3 days ago

$MDGL Peak Sales Estimates.... Please add any I'm missing Evercore ISI $5.5 billion Jefferies $3.4 billion Piper Sandler $5 billion Leerink $3.5 billion GlobalData $1.64 billion Goldman Sachs $4.1 billion TD Cowen $4.9 billion

precise Posted - 3 days ago

Either $VKTX or $MDGL gets bought out in Q3 this year and I think the bidding will be highly competitive.